Through integrated investigation in both 3T3-L1 adipocytes and ob/ob mice, we show that EMO co-treatment synergistically enhances RSG’s glucose-lowering and insulin-sensitizing effects while effectively mitigating RSG-induced weight gain, adipocyte hypertrophy, and hepatic steatosis. Here, INS is linked to fatty liver disease.